Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue

Natera, Inc. (NASDAQ:NTRA) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood.

Natera, Inc. (NASDAQ:NTRA) announced preliminary fourth-quarter 2025 revenue of $660 million, exceeding the average forecast of $577.62 million, as reported by TheFly on January 12, 2026. Revenue for the entire year of 2025 was $2.3 billion, above the $2.22 billion estimate. Approximately 923,600 tests were processed in Q4, a 17% surge from 792,800 in Q4 2024. The total number of tests processed in FY25 was approximately 3,525,500, up 15% from 3,064,600 in 2024. CEO Steve Chapman noted record gains in the areas of women’s health, organ health, and oncology. He noted substantial spikes in volume, revenue, and gross margins and expressed confidence in the company’s ongoing growth through 2026.

On January 7, 2026, TD Cowen maintained its Buy recommendation and increased its price goal for Natera, Inc. (NASDAQ:NTRA) from $240 to $280. The company noted that the corporation’s fundamentals are still strong, citing solid Q4 earnings and a promising 2026 outlook for the diagnostics industry.

Natera, Inc. (NASDAQ:NTRA) is a research and diagnostic firm that uses exclusive molecular and bioinformatics technology.

While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 20 Best Performing Stocks in 2025 and 12 Best Food Stocks to Buy in 2026. 

Disclosure: None. This article is originally published at Insider Monkey.